136 related articles for article (PubMed ID: 7629426)
1. Skeletal alkaline phosphatase as a serum marker of bone metastases in the follow-up of patients with breast cancer.
Reale MG; Santini D; Marchei GG; Manna A; Del Nero A; Bianco V; Marchei P; Frati L
Int J Biol Markers; 1995; 10(1):42-6. PubMed ID: 7629426
[TBL] [Abstract][Full Text] [Related]
2. Isoenzymes of alkaline and acid phosphatases as bones metastasis marker in breast cancer patients.
Desoize B; Veiler V; Pourny C; Comoe L; Jardillier JC
Anticancer Res; 1989; 9(4):1105-9. PubMed ID: 2817792
[TBL] [Abstract][Full Text] [Related]
3. Significance of bone alkaline phosphatase, CA 15-3 and CEA in the detection of bone metastases during the follow-up of patients suffering from breast carcinoma.
Stieber P; Nagel D; Ritzke C; Rössler N; Kirsch CM; Eiermann W; Fateh-Moghadam A
Eur J Clin Chem Clin Biochem; 1992 Dec; 30(12):809-14. PubMed ID: 1489855
[TBL] [Abstract][Full Text] [Related]
4. Serum ostase in the follow-up of breast cancer patients.
Marchei P; Santini D; Bianco V; Chiodini S; Reale MG; Simeoni F; Marchei GG; Vecchione A
Anticancer Res; 1995; 15(5B):2217-22. PubMed ID: 8572628
[TBL] [Abstract][Full Text] [Related]
5. Plasma acid and alkaline phosphatase in patients with breast cancer.
Nguyen M; Bonneterre J; Hecquet B; Desoize B; Demaille A
Anticancer Res; 1991; 11(2):831-3. PubMed ID: 2064338
[TBL] [Abstract][Full Text] [Related]
6. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
Amico S; Liehn JC; Desoize B; Larbre H; Deltour G; Valeyre J
Clin Nucl Med; 1991 Sep; 16(9):643-8. PubMed ID: 1718651
[TBL] [Abstract][Full Text] [Related]
7. Identification of bone and liver metastases from breast cancer by measurement of plasma alkaline phosphatase isoenzyme activity.
Mayne PD; Thakrar S; Rosalki SB; Foo AY; Parbhoo S
J Clin Pathol; 1987 Apr; 40(4):398-403. PubMed ID: 3584482
[TBL] [Abstract][Full Text] [Related]
8. Monitoring skeletal cancer metastases with the bone isoenzyme of tissue unspecific alkaline phosphatase.
Burlina A; Rubin D; Secchiero S; Sciacovelli L; Zaninotto M; Plebani M
Clin Chim Acta; 1994 May; 226(2):151-8. PubMed ID: 7923810
[TBL] [Abstract][Full Text] [Related]
9. Study of serum tumor markers CEA, CA 15.3 and CA 27.29 as diagnostic parameters in patients with breast carcinoma.
Rodríguez de Paterna L; Arnaiz F; Estenoz J; Ortuño B; Lanzós E
Int J Biol Markers; 1995; 10(1):24-9. PubMed ID: 7629423
[TBL] [Abstract][Full Text] [Related]
10. Serum bone alkaline phosphatase in the follow-up of skeletal metastases.
Zaninotto M; Secchiero S; Rubin D; Sciacovelli L; Trovò M; Bortolus R; Plebani M
Anticancer Res; 1995; 15(5B):2223-8. PubMed ID: 8572629
[TBL] [Abstract][Full Text] [Related]
11. Expressiveness of Bone Markers in Breast Cancer with Bone Metastases.
Zulauf N; Brüggmann D; Groneberg D; Oremek GM
Oncology; 2019; 97(4):236-244. PubMed ID: 31412345
[TBL] [Abstract][Full Text] [Related]
12. The bone isoenzyme of alkaline phosphatase in hypercalcaemic cancer patients.
Body JJ; Dumon JC; Blocklet D; Darte C
Eur J Cancer; 1997 Sep; 33(10):1578-82. PubMed ID: 9389918
[TBL] [Abstract][Full Text] [Related]
13. Alkaline phosphatase isoenzymes in detection and follow up of breast cancer metastases.
Ritzke C; Stieber P; Untch M; Nagel D; Eiermann W; Fateh-Moghadam A
Anticancer Res; 1998; 18(2B):1243-9. PubMed ID: 9615795
[TBL] [Abstract][Full Text] [Related]
14. Serum bone alkaline phosphatase and CA 549 in breast cancer with bone metastases.
Cooper EH; Forbes MA; Hancock AK; Parker D; Laurence V
Biomed Pharmacother; 1992; 46(1):31-6. PubMed ID: 1421033
[TBL] [Abstract][Full Text] [Related]
15. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Chung YC; Ku CH; Chao TY; Yu JC; Chen MM; Lee SH
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):424-8. PubMed ID: 16537696
[TBL] [Abstract][Full Text] [Related]
16. Lectin affinity electrophoresis of serum alkaline phosphatase in metastasized breast cancer.
Le Bricon T; Gay-Bellile C; Cottu P; Benlakehal M; Guillon H; Houzé P
J Clin Lab Anal; 2010; 24(1):20-4. PubMed ID: 20087950
[TBL] [Abstract][Full Text] [Related]
17. Method for determination of bone alkaline phosphatase activity: analytical performance and clinical usefulness in patients with metabolic and malignant bone diseases.
Withold W; Schulte U; Reinauer H
Clin Chem; 1996 Feb; 42(2):210-7. PubMed ID: 8595712
[TBL] [Abstract][Full Text] [Related]
18. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis.
Tsai SH; Chen CY; Ku CH; Janckila AJ; Yam LT; Yu JC; Chuang KW; Chao TY
Mayo Clin Proc; 2007 Aug; 82(8):917-26. PubMed ID: 17673059
[TBL] [Abstract][Full Text] [Related]
19. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer.
Montravers F; Younsi N; Rousseau C; Philippe C; Seddiki M; Uzan S; Izrael V; Talbot JN
Anticancer Res; 1997; 17(3B):1683-6. PubMed ID: 9179218
[TBL] [Abstract][Full Text] [Related]
20. Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma.
Desoize B; Amico S; Larbre H; Coninx P; Jardillier JC
Clin Biochem; 1991 Oct; 24(5):443-6. PubMed ID: 1760884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
